Anlon Healthcare Limited
Promoters PUNITKUMAR R. RASADIA · MEET ATULKUMAR VACHHANI · MAMATA PUNITKUMAR RASADIA
Anlon Healthcare Limited raised ₹121 crore through a mainboard initial public offer.
The filing places it in Pharmaceuticals & Biotechnology and names three promoters: PUNITKUMAR R. RASADIA, MEET ATULKUMAR VACHHANI and MAMATA PUNITKUMAR RASADIA.
The book was open from 25 August 2025 to 29 August 2025.
The issue was priced at ₹91 a share, from a band of ₹86 to ₹91.
The whole offer is a fresh issue of shares — ₹121 crore raised by the company itself.
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
The shares listed on 3 September 2025.
We hold no exchange price bars for this ISIN yet.
No offer-for-sale leg — every share in this offer is newly issued, so the whole amount raised goes to the company.
- Registrar
- KFintech Private Limited
- Lead manager
- Other LM / BRLM
- Bidding opens25 Aug 2025
- Bidding closes29 Aug 2025
- Basis of allotmentnot published
Not published in the exchange feeds we ingest — we do not estimate it.
- Listing3 Sept 2025
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
We have not extracted an anchor allotment list for this issue.
- All other pre-issue capitalSEBI ICDR 2018 Reg. 17 — all other pre-issue capital, 6 months from allotment3 Mar 2026already free
- Promoters' minimum contributionSEBI ICDR 2018 Reg. 16(1)(a) — promoters' minimum contribution, 18 months from allotment3 Mar 2027whole tranche releases on this date
Computed from the SEBI ICDR 2018 lock-in rules, not disclosed by the issuer or the exchange. The regulation counts from the date of allotment, which no feed we ingest publishes, so these are counted from the listing date and fall at most two to three business days later than the true expiry.
Every offer document must set out the reasoning behind its own price: what the company earned in the years before it came to market, and what multiple of those earnings it is asking for. This is that chapter — the issuer’s argument for its price, not our assessment of it.
Figures as printed in the offer document's "Basis for Offer Price" chapter. A record of the case the issuer made for its own price, not our valuation of it.
Everything we extracted from this issue's offer document is the pricing justification rather than the restated statements — it is shown under how the offer was priced. The restated financial statements themselves have not been extracted for this issue.
We have not extracted this section from the offer document for this issue yet. It is read from the abridged prospectus, and several offer documents are served as .zip archives or as scanned pages with no text layer.
The offer document must name the listed companies the issuer considers comparable, and print their valuation figures beside its own. This is that list — the issuer’s choice of comparison, not ours.
| Company | P/E | P/B | RoNW | EPS | Income |
|---|---|---|---|---|---|
| Acutaas Chemicals Limited | 58.5 | — | 12.2% | — | — |
| Kronox Lab Sciences Limited | 26.2 | — | 28.3% | — | ₹10,272 cr |
The issuer's own figures as printed at the head of the same table — its claim about itself, on the same basis as its claims about the companies below.
Figures as PRINTED by the issuer in its own offer document. The comparison set is the issuer's choice, not ours.
| Firm | Issues | Typical listing move | Below issue @30d | @90d | @180d |
|---|---|---|---|---|---|
KFintech Private Limited 2023 – 2026 | 67 2 measurable | +35.7% | 2 of 5 | 4 of 8 | 1 of 2 |
A count of what happened to the other issues each firm was named on, computed from exchange closes. Not a rating, not a ranking, and not a view on the firm.
- Prospectus· PDF · exchange archive1 Sept 2025
- Draft red herring prospectus (DRHP)· PDF · exchange archive19 Apr 2025
- Draft red herring prospectus (DRHP)· PDF · exchange archive20 Feb 2025
- Draft red herring prospectus (DRHP)· ZIP · exchange archive26 Dec 2024
- Draft red herring prospectus (DRHP)· ZIP · exchange archive10 Oct 2024
- In-principle approval (XBRL)· XML · exchange archive
- Listing filing (XBRL)· XML · exchange archive
Filed with SEBI and the exchanges by the issuer. These are the source for every figure on this page.
Compiled from NSE and SEBI offer documents and exchange feeds. A description of the issue and of the bids received — not investment advice, and not a view on whether to apply. No grey-market premium, no allotment lookup and no listing-gain estimate is published here.